This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
n12	http://dx.doi.org/10.1093/ECCO-JCC/
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n9	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q91329599

rdf:type

wikibase:Item

schema:description

wetenschappelijk artikel scientific article published on 01 July 2019 наукова стаття, опублікована 1 липня 2019 artículu científicu espublizáu en xunetu de 2019 article scientifique publié en 2019 im Juli 2019 veröffentlichter wissenschaftlicher Artikel

p:P577

wds:Q91329599-E2664A15-075C-463B-AB67-EC1F05C35CA5

wdt:P577

2019-07-01T00:00:00Z

p:P2093

wds:Q91329599-205EBE6A-050C-459E-B069-1CC74A6AF7AB wds:Q91329599-79DBBBC5-E120-400F-842E-75CE9521F0FE wds:Q91329599-AA5800E8-19D5-4002-8216-20D7FC2F30CC wds:Q91329599-C407B930-3FCD-4E15-BB40-09969F861BB3

wdt:P2093

An Outtier Gert Van Assche Isolde Aerden Ann Gils

rdfs:label

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

skos:prefLabel

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

schema:name

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

p:P50

wds:Q91329599-0C118F4C-9900-4E84-AFD4-0B2958BA2C9E wds:Q91329599-5A161D94-7E2D-494B-9BF7-05548600876C wds:Q91329599-852AFA4A-B409-4C9E-A9E0-A4DE2E241158 wds:Q91329599-D9A8FDF1-472B-4444-882B-9BB14526C5A5 wds:Q91329599-F2C1C7B4-D4B3-425C-9E71-13C8277F5888 wds:Q91329599-F35A5084-4242-4EB0-A144-788AE99C5376 wds:Q91329599-BE843119-C65A-412A-BB5C-C493244A99D4

wdt:P50

wd:Q90028549 wd:Q56849487 wd:Q89598104 wd:Q30247983 wd:Q114416531 wd:Q110729292 wd:Q114416386

p:P1476

wds:Q91329599-57063889-C638-4DFD-BAA2-73446D76823F

wdt:P1476

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates

p:P304

wds:Q91329599-C5F9BA16-0156-4E03-AABD-C94DCFB408A0

wdt:P304

864-872

p:P31

wds:Q91329599-A3D523B6-3DB8-4472-B504-B21746D4814E

wdt:P31

wd:Q13442814

p:P921

wds:Q91329599-E41F323C-E19C-4AF3-A943-50ECB7DACCAF

wdt:P921

wd:Q1472

p:P698

wds:Q91329599-9B0D18C4-F2D2-443F-993C-C01CB686CA2E

wdtn:P698

n9:30715258

wdt:P698

30715258

p:P1433

wds:Q91329599-492019C8-E062-4AC5-8943-0B8F3E19B313

wdt:P1433

wd:Q15817379

p:P433

wds:Q91329599-C5F3C608-57AD-42C7-A778-C0673B3A9E48

p:P478

wds:Q91329599-C2AE1C45-6BCA-4E51-80D7-9BACFDE9223F

wdt:P433

7

wdt:P478

13

p:P356

wds:Q91329599-D9F8B802-D40F-4C03-9E6C-DDA1D2F0B710

wdtn:P356

n12:JJZ008

wdt:P356

10.1093/ECCO-JCC/JJZ008